Importance: The rapidly growing legal cannabis market includes new and highly potent products, the effects of which, to our knowledge, have not previously been examined in biobehavioral research studies because of federal restrictions on cannabis research. Objective: To use federally compatible, observational methods to study high-∆9-tetrahydrocannabinol (THC) legal market forms of cannabis. Design, Setting, and Participants: In this cohort study with a between-groups design that was conducted in a community and university setting, cannabis flower users and concentrate users were randomly assigned to higher- vs lower-THC products within user groups. Participants completed a baseline and an experimental mobile laboratory assessment that included 3 points: before, immediately after, and 1 hour after ad libitum legal market flower and concentrate use. Of the 133 individuals enrolled and assessed, 55 regular flower cannabis users (41.4%) and 66 regular concentrate cannabis users (49.6%) complied with the study's cannabis use instructions and had complete data across primary outcomes. Exposures: Flower users were randomly assigned to use either 16% or 24% THC flower and concentrate users were randomly assigned to use either 70% or 90% THC concentrate that they purchased from a dispensary. Main Outcomes and Measures: Primary outcome measures included plasma cannabinoids, subjective drug intoxication, and neurobehavioral tasks testing attention, memory, inhibitory control, and balance. Results: A total of 121 participants completed the study for analysis: 55 flower users (mean [SD] age, 28.8 [8.1] years; 25 women [46%]) and 66 concentrate users (mean [SD] age, 28.3 [10.4] years; 30 women [45%]). Concentrate users compared with flower users exhibited higherplasma THC levels and 11-hydroxyΔ9-THC (THC's active metabolite) across all points. After ad libitum cannabis administration, mean plasma THC levels were 0.32 (SE = 0.43) μg/mL in concentrate users (to convert to millimoles per liter, multiply by 3.18) and 0.14 (SE = 0.16) μg/mL in flower users. Most neurobehavioral measures were not altered by short-term cannabis consumption. However, delayed verbal memory (F1,203 = 32.31; P < .001) and balance function (F1,203 = 18.88; P < .001) were impaired after use. Differing outcomes for the type of product (flower vs concentrate) or potency within products were not observed. Conclusions and Relevance: This study provides information about the association of pharmacological and neurobehavioral outcomes with legal market cannabis. Short-term use of concentrates was associated with higher levels of THC exposure. Across forms of cannabis and potencies, users' domains of verbal memory and proprioception-focused postural stability were primarily associated with THC administration.
RCT Entities:
Importance: The rapidly growing legal cannabis market includes new and highly potent products, the effects of which, to our knowledge, have not previously been examined in biobehavioral research studies because of federal restrictions on cannabis research. Objective: To use federally compatible, observational methods to study high-∆9-tetrahydrocannabinol (THC) legal market forms of cannabis. Design, Setting, and Participants: In this cohort study with a between-groups design that was conducted in a community and university setting, cannabis flower users and concentrate users were randomly assigned to higher- vs lower-THC products within user groups. Participants completed a baseline and an experimental mobile laboratory assessment that included 3 points: before, immediately after, and 1 hour after ad libitum legal market flower and concentrate use. Of the 133 individuals enrolled and assessed, 55 regular flower cannabis users (41.4%) and 66 regular concentrate cannabis users (49.6%) complied with the study's cannabis use instructions and had complete data across primary outcomes. Exposures: Flower users were randomly assigned to use either 16% or 24% THC flower and concentrate users were randomly assigned to use either 70% or 90% THC concentrate that they purchased from a dispensary. Main Outcomes and Measures: Primary outcome measures included plasma cannabinoids, subjective drug intoxication, and neurobehavioral tasks testing attention, memory, inhibitory control, and balance. Results: A total of 121 participants completed the study for analysis: 55 flower users (mean [SD] age, 28.8 [8.1] years; 25 women [46%]) and 66 concentrate users (mean [SD] age, 28.3 [10.4] years; 30 women [45%]). Concentrate users compared with flower users exhibited higher plasma THC levels and 11-hydroxyΔ9-THC (THC's active metabolite) across all points. After ad libitum cannabis administration, mean plasma THC levels were 0.32 (SE = 0.43) μg/mL in concentrate users (to convert to millimoles per liter, multiply by 3.18) and 0.14 (SE = 0.16) μg/mL in flower users. Most neurobehavioral measures were not altered by short-term cannabis consumption. However, delayed verbal memory (F1,203 = 32.31; P < .001) and balance function (F1,203 = 18.88; P < .001) were impaired after use. Differing outcomes for the type of product (flower vs concentrate) or potency within products were not observed. Conclusions and Relevance: This study provides information about the association of pharmacological and neurobehavioral outcomes with legal market cannabis. Short-term use of concentrates was associated with higher levels of THC exposure. Across forms of cannabis and potencies, users' domains of verbal memory and proprioception-focused postural stability were primarily associated with THC administration.
Authors: Wendy M Bosker; Kim P C Kuypers; Eef L Theunissen; Anke Surinx; Roos J Blankespoor; Gisela Skopp; Wayne K Jeffery; H Chip Walls; Cees J van Leeuwen; Johannes G Ramaekers Journal: Addiction Date: 2012-07-12 Impact factor: 6.526
Authors: Claudine C Hunault; Koen B E Böcker; R K Stellato; J Leon Kenemans; Irma de Vries; Jan Meulenbelt Journal: Psychopharmacology (Berl) Date: 2014-05-31 Impact factor: 4.530
Authors: Jarrod M Ellingson; Jesse D Hinckley; J Megan Ross; Joseph P Schacht; L Cinnamon Bidwell; Angela D Bryan; Christian J Hopfer; Paula Riggs; Kent E Hutchison Journal: Curr Behav Neurosci Rep Date: 2021-11-15
Authors: Laurel P Gibson; Hollis C Karoly; Jarrod M Ellingson; Jost Klawitter; Cristina Sempio; Julia E Squeri; Angela D Bryan; L Cinnamon Bidwell; Kent E Hutchison Journal: Addict Biol Date: 2021-08-31 Impact factor: 4.093
Authors: Hollis C Karoly; Michael A Milburn; Ashley Brooks-Russell; Mary Brown; Jessica Streufert; Angela D Bryan; Nicholas P Lovrich; William DeJong; L Cinnamon Bidwell Journal: Cannabis Cannabinoid Res Date: 2020-09-10
Authors: Christine M Steeger; Leah N Hitchcock; Angela D Bryan; Kent E Hutchison; Karl G Hill; L Cinnamon Bidwell Journal: Int J Drug Policy Date: 2021-05-30
Authors: Laurel P Gibson; Charleen J Gust; Jarrod M Ellingson; Sophie L YorkWilliams; Cristina Sempio; Jost Klawitter; Angela D Bryan; Kent E Hutchison; L Cinnamon Bidwell Journal: Drug Alcohol Depend Date: 2021-04-20 Impact factor: 4.852
Authors: Cristina Sempio; L Cinnamon Bidwell; Kent Hutchison; Marilyn A Huestis; Jost Klawitter; Uwe Christians; Thomas K Henthorn Journal: Ther Drug Monit Date: 2021-08-01 Impact factor: 3.118
Authors: Angela K Stevens; Elizabeth R Aston; Rachel L Gunn; Alexander W Sokolovsky; Hayley Treloar Padovano; Helene R White; Kristina M Jackson Journal: Alcohol Clin Exp Res Date: 2020-11-26 Impact factor: 3.928